Literature DB >> 33572233

Immunogenicity Assessment of Different Segments and Domains of Group a Streptococcal C5a Peptidase and Their Application Potential as Carrier Protein for Glycoconjugate Vaccine Development.

Guirong Wang1, Jielin Zhao1, Yisheng Zhao1, Subo Wang1, Shaojie Feng1, Guofeng Gu1.   

Abstract

Group A streptococcal C5a peptidase (ScpA) is a highly conserved surface virulence factor present on group A streptococcus (GAS) cell surfaces. It has attracted much more attention as a promising antigenic target for GAS vaccine development due to its high antigenicity to stimulate specific and immunoprotective antibodies. In this study, a series of segments of ScpA were rationally designed according to the functional domains described in its crystal structure, efficiently prepared and immunologically evaluated so as to assess their potential as antigens for the development of subunit vaccines. Immunological studies revealed that Fn, Fn2, and rsScpA193 proteins were promising antigen candidates worthy for further exploration. In addition, the potential of Fn and Fn2 as carrier proteins to formulate effective glycoconjugate vaccine was also investigated.

Entities:  

Keywords:  carrier protein; group A streptococcal C5a peptidase; group A streptococcus; immunogenicity; subunit protein vaccine

Year:  2021        PMID: 33572233      PMCID: PMC7915350          DOI: 10.3390/vaccines9020139

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  50 in total

1.  Group A streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection.

Authors:  Hemant Sabharwal; Francis Michon; Daniel Nelson; Wenling Dong; Kathleen Fuchs; Roberto Carreno Manjarrez; Arun Sarkar; Catherine Uitz; Ann Viteri-Jackson; Romeo S Rodriguez Suarez; Milan Blake; John B Zabriskie
Journal:  J Infect Dis       Date:  2005-11-29       Impact factor: 5.226

Review 2.  Pathogenesis of group A streptococcal infections and their sequelae.

Authors:  Madeleine W Cunningham
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

3.  New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci.

Authors:  James B Dale; Thomas A Penfound; Edna Y Chiang; William J Walton
Journal:  Vaccine       Date:  2011-09-13       Impact factor: 3.641

4.  Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.

Authors:  Shelly A McNeil; Scott A Halperin; Joanne M Langley; Bruce Smith; Andrew Warren; Geoffrey P Sharratt; Darlene M Baxendale; Mark A Reddish; Mary C Hu; Steven D Stroop; Janine Linden; Louis F Fries; Peter E Vink; James B Dale
Journal:  Clin Infect Dis       Date:  2005-09-12       Impact factor: 9.079

5.  Gold nanoparticles morphology does not affect the multivalent presentation and antibody recognition of Group A Streptococcus synthetic oligorhamnans.

Authors:  Olimpia Pitirollo; Francesca Micoli; Francesca Necchi; Francesca Mancini; Martina Carducci; Roberto Adamo; Claudio Evangelisti; Laura Morelli; Laura Polito; Luigi Lay
Journal:  Bioorg Chem       Date:  2020-04-03       Impact factor: 5.275

6.  Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development.

Authors:  Anita Shet; Edward L Kaplan; Dwight R Johnson; P Patrick Cleary
Journal:  J Infect Dis       Date:  2003-09-04       Impact factor: 5.226

7.  C5a peptidase alters clearance and trafficking of group A streptococci by infected mice.

Authors:  Y Ji; L McLandsborough; A Kondagunta; P P Cleary
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

8.  Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.

Authors:  Karen L Kotloff; Mary Corretti; Kathleen Palmer; James D Campbell; Mark A Reddish; Mary C Hu; Steven S Wasserman; James B Dale
Journal:  JAMA       Date:  2004-08-11       Impact factor: 56.272

9.  Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case.

Authors:  Giuliano Bensi; Marirosa Mora; Giovanna Tuscano; Massimiliano Biagini; Emiliano Chiarot; Mauro Bombaci; Sabrina Capo; Fabiana Falugi; Andrea G O Manetti; Paolo Donato; Erwin Swennen; Marilena Gallotta; Manuela Garibaldi; Vittoria Pinto; Nico Chiappini; James M Musser; Robert Janulczyk; Massimo Mariani; Maria Scarselli; John L Telford; Renata Grifantini; Nathalie Norais; Immaculada Margarit; Guido Grandi
Journal:  Mol Cell Proteomics       Date:  2012-01-27       Impact factor: 5.911

10.  Vaccine-Induced Th1-Type Response Protects against Invasive Group A Streptococcus Infection in the Absence of Opsonizing Antibodies.

Authors:  Tania Rivera-Hernandez; Mira Syahira Rhyme; Amanda J Cork; Scott Jones; Celia Segui-Perez; Livia Brunner; Johanna Richter; Nikolai Petrovsky; Maria Lawrenz; David Goldblatt; Nicolas Collin; Mark J Walker
Journal:  mBio       Date:  2020-03-10       Impact factor: 7.867

View more
  1 in total

1.  GMMA as an Alternative Carrier for a Glycoconjugate Vaccine against Group A Streptococcus.

Authors:  Elena Palmieri; Zoltán Kis; James Ozanne; Roberta Di Benedetto; Beatrice Ricchetti; Luisa Massai; Martina Carducci; Davide Oldrini; Gianmarco Gasperini; Maria Grazia Aruta; Omar Rossi; Cleo Kontoravdi; Nilay Shah; Fatme Mawas; Francesca Micoli
Journal:  Vaccines (Basel)       Date:  2022-06-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.